Clinical Report: Comparison of Adjuvanted and High-Dose Influenza Vaccines
Overview
This study evaluates the relative vaccine effectiveness (rVE) of adjuvanted versus high-dose influenza vaccines in adults aged 65 years and older. Conducted at Kaiser Permanente Northern California, the findings indicate comparable effectiveness in preventing laboratory-confirmed influenza during the 2023 to 2024 season.
Background
Influenza poses a significant health risk to older adults, who account for a large proportion of influenza-related hospitalizations and deaths. The U.S. Advisory Committee on Immunization Practices recommends enhanced vaccines for this population to improve immune responses. However, direct comparisons of adjuvanted and high-dose vaccines have been limited, highlighting the need for this study.
Data Highlights
No numerical data available in the provided material.
Key Findings
The study involved adults aged 65 years or older receiving either adjuvanted or high-dose influenza vaccines.
Vaccine effectiveness was assessed during the 2023 to 2024 influenza season.
Both vaccine types were administered in a cluster randomized crossover design across KPNC facilities.
Adjuvanted and high-dose vaccines have shown comparable effectiveness in preventing influenza-related medical encounters.
Clinical Implications
Healthcare providers should consider the comparable effectiveness of adjuvanted and high-dose influenza vaccines when vaccinating older adults. This study supports ongoing recommendations for enhanced vaccine use in this vulnerable population.
Conclusion
The findings from this study contribute to the understanding of influenza vaccine effectiveness in older adults, reinforcing the importance of vaccination strategies tailored to this demographic.
by Amber Hsiao, Thomas Leong, Bruce Fireman, John Hansen, Ousseny Zerbo, Karen B. Jacobson, Lauren D. Liao, Mendel D. M. Haag, Ian McGovern, Bin Zhang, Juliet Dang, Nicola P. Klein
